

EN

***Case No COMP/M.7294 - CARLYLE/ HAIER GROUP/ HAIER
BIOMEDICAL AND LABORATORY PRODUCT***

Only the English text is available and authentic.

**REGULATION (EC) No 139/2004
MERGER PROCEDURE**

Article 6(1)(b) NON-OPPOSITION

Date: 08/07/2014

***In electronic form on the EUR-Lex website under document
number 32014M7294***



EUROPEAN COMMISSION

Brussels, 8.7.2014
C(2014) 4947 final

PUBLIC VERSION

SIMPLIFIED MERGER
PROCEDURE

To the notifying parties

Dear Madam(s) and/or Sir(s),

Subject: Case M.7294 - CARLYLE/ HAIER GROUP/ HAIER BIOMEDICAL AND LABORATORY PRODUCT
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004¹

1. On 6 June 2014, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which the Carlyle Group L.P. ('Carlyle', USA) and Haier Group Corporation ('Haier Group', China) intend to acquire within the meaning of Art. 3 (1)(b) of the Merger Regulation joint control of the undertaking Haier Biomedical and Laboratory Products Co., Ltd. ('HBML', China), currently solely controlled by the Haier Group².
2. The business activities of the undertakings concerned are:
 - for Carlyle: global alternative asset manager;

¹ OJ L 24, 29.1.2004, p. 1 ('the Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

² Publication in the Official Journal of the European Union No C 185, 17.6.2014, p. 46.

- for Haier Group: multinational manufacturer and supplier of consumer electronics and home appliances;
 - for HBML: supplier of general laboratory equipment, in particular medical freezers, medical fridges/deep freezers and biomedical safety hoods.
3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(a) and 5(c) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.³
 4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation.

For the Commission
(Signed)
Alexander ITALIANER
Director-General

³ OJ C 366, 14.12.2013, p. 5.